Stopping nucleos(t)ide analogues treatment in non-cirrhotic HBeAg-negative patients: Yes, we can!

Third generation nucleos(t)ide analogues (NA): Entecavir (ETV), Tenofovir Disoproxil (TDF) and Tenofovir Alafenamide (TAF) efficiently block viral replication and, on long-term, may halt the progression of liver disease reducing the occurrence of hepatocellular carcinoma and hepatic decompensation, prolonging patient's survival. While NA therapy can be stopped in HBeAg-positive patients with HBeAg seroconversion and>1 year consolidation therapy, long-term NA treatment has been recommended for HBeAg-negative chronic hepatitis B (CHB) patients until HBsAg clearance [1,2].
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Tags: Commentary Source Type: research